Mechanisms of resistance to PARP inhibitors--three and counting

Given the malleable nature of cancer cells, we should expect, and do see, the development of resistance to any new chemotherapeutic agent. Models that help us understand how this happens are a first step to better and more effective chemotherapeutics.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2013-01, Vol.3 (1), p.20-23
Hauptverfasser:	Fojo, Tito, Bates, Susan
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - therapeutic use Chromosomal Proteins, Non-Histone - genetics DNA-Binding Proteins - genetics Drug Resistance, Neoplasm Enzyme Inhibitors - therapeutic use Female Phthalazines - therapeutic use Piperazines - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors Tumor Suppressor p53-Binding Protein 1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Given the malleable nature of cancer cells, we should expect, and do see, the development of resistance to any new chemotherapeutic agent. Models that help us understand how this happens are a first step to better and more effective chemotherapeutics.
ISSN:	2159-8274 2159-8290
DOI:	10.1158/2159-8290.cd-12-0514